ARTICLE | Product Development
Five approaches to drug cancer’s ‘undruggable’ β-catenin pathway
Clinical companies are targeting five different nodes to separate oncogenic signaling from Wnt’s roles in healthy tissue
August 12, 2026 11:53 PM UTC
A new generation of Wnt pathway inhibitors aims to avoid the toxicities that sank earlier attempts to disrupt β-catenin signaling. But rather than converge on a single solution, five clinical programs are pursuing five different points of intervention along the pathway.
Dewpoint Therapeutics Inc., Iterion Therapeutics Inc., Sapience Therapeutics Inc., Parabilis Medicines Inc. (NASDAQ:PBLS), and partners PRISM BioLab Co. Ltd. and Eisai Co. Ltd. (TSE:4523) all have molecules in the clinic, each inhibiting β-catenin signaling in a different way...